Ovarian cancer has the characteristics of difficulty in early diagnosis, easy recurrence and resistance, so its mortality rate ranks first in gynecological tumors. Existing treatment methods such as surgery, radiotherapy and chemotherapy are not very effective, thus immunotherapy has emerged. Immune checkpoint programmed death-1 (PD-1) and its ligand PD-L1 can inhibit T cell proliferation and mediate tumor immune escape. At present, PD-1/PD-L1 inhibitors have made breakthrough progress in a variety of solid tumors, and they have achieved initial efficacy in clinical treatment of ovarian cancer.